Skip to main content

Table 2 Comparison of arginase activity, mediators of inflammation and peripheral blood immunophenotype, between the different groups

From: Elevated levels of arginase activity are related to inflammation in patients with COPD exacerbation

 

N

Group (I)a

Group (II)a

Group (III)a

Group (IV)a

p I + II

p I + III

p II + III

p III + IV

p II + IV

Actarginase (µmol urea/min)

49

0.500 (0.122)

0.521 (0.217)

0.70 (0.33)

0.59 (0.32)

0.720

0.042

0.067

0.357

0.483

CRP (mg/L)

49

0.551 (0.685)

0.689 (0.750)

1.283 (1.200)

2.602 (3.110)

0.445

0.027

0.061

0.038

0.147

IL-6 (pg/ml)

37

13.45 (1.992)

10.74 (1.040)

14.54 (4.87)

15.57 (2.58)

0.001

0.522

0.037

0.643

0.005

IL-8 (pg/ml)

37

64.53 (17.13)

53.49 (9.65)

69.86 (15.46)

70.89 (17.70)

0.081

0.475

0.008

0.904

0.018

TNF-a (pg/ml)

37

100.0 (12.72)

98.54 (12.95)

95.70 (10.56)

94.72 (18.75)

0.797

0.421

0.591

0.902

0.660

INF-γ (pg/ml)

37

58.22 (8.285)

75.62 (25.29)

89.30 (9.97)

87.42 (4.96)

0.051

 < 0.001

0.121

0.675

0.162

Neutrophils (%)

49

61.57 (8.13)

62.12 (7.60)

78.76 (12.93)

62.78 (10.18)

0.841

 < 0.001

 < 0.001

0.001

0.832

Lymphocytes (%)

49

28.85 (7.49)

27.77 (7.35)

15.31 (9.48)

27.47 (8.92)

0.675

 < 0.001

 < 0.001

0.001

0.917

CD3 (%)

49

72.25 (7.01)

72.02 (8.90)

66.46 (12.67)

73.07 (9.64)

0.935

0.135

0.142

0.127

0.749

CD4 (%)

49

48.66 (8.64)

42.90 (11.72)

41.01 (9.83)

42.46 (8.21)

0.122

0.032

0.619

0.670

0.905

CD8 (%)

49

22.21 (9.32)

29.02 (9.99)

25.00 (6.75)

29.82 (11.60)

0.050

0.355

0.192

0.179

0.832

MC CD16+ (%)

49

21.20 (7.57)

23.79 (13.63)

17.00 (9.07)

18.00 (9.84)

0.488

0.186

0.116

0.786

0.199

MC CD16− (%)

49

78.87 (7.41)

78.00 (12.01)

83.93 (9.97)

83.36 (10.64)

0.809

0.131

0.147

0.885

0.199

CD3ζ (%)b

49

77.58 (22.42)

69.39 (40.75)

64.86 (46.75)

68.36 (43.75)

0.382

0.291

0.699

0.773

0.913

NKCD56++ (%)b

49

4.24 (3.74)

4.63 (4.76)

2.13 (2.31)

3.18 (3.40)

0.812

0.089

0.047

0.237

0.338

CD3ζNK (%)b

49

94.20 (1.00)

98.61 (0.00)

81.12 (29.55)

93.48 (14.75)

0.330

0.174

0.053

0.169

0.061

Monocyte (%)b

49

6.44 (2.38)

6.626 (2.70)

4.580 (3.55)

8.76 (1.35)

0.759

0.026

0.013

0.127

0.415

  1. Data expressed as mean and standard deviation unless otherwise indicated
  2. IL-6, Interleukin 6; IL-8, Interleukin 8; IFN-γ, Interferon gamma; TNF-∝, Tumor necrosis factor alpha; ActArginase, arginase activity, MC CD16+, CD16+ monocytes (non-classical); MC CD16−, Monocytes CD16− (classic)
  3. aGroup I: control; Group II: stable COPD; Group III: exacerbated phase COPD. The subjects in the fourth group: COPD 3 months after exacerbation (IV), are the same than the ones from group III
  4. bVariables with non-normal distribution: the median value and the inter-quartile range are shown in parentheses. Comparison with the Mann–Whitney test
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us